Filing Flows › Comparisons › CUE vs XENE
Cue Biopharma vs Xenon Pharmaceuticals: CUE and XENE compared
Cue Biopharma is the larger company: $7.9M of revenue in its latest quarter (Q2 2026) against $7.5M for Xenon Pharmaceuticals (Q1 2025).
Where the money goes: CUE and XENE
Cue Biopharma (CUE) · Q2 2026
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Xenon Pharmaceuticals (XENE) · Q1 2025
Xenon Pharmaceuticals, Q1 2025: revenue $7.5M, operating margin -969.8%, net loss $65.0M, operating cash flow −$61.7M. The chart follows the revenue to costs, profit and cash.
| Cue Biopharma (CUE) | Xenon Pharmaceuticals (XENE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2025 |
| Revenue | $7.9M | $7.5M |
| Revenue growth, Y/Y | +167% | — |
| Operating margin | n/m | -969.8% |
| Net earnings | −$153M | −$65.0M |
| Net margin | — | -867.3% |
| Operating cash flow | −$29.0M | −$61.7M |
| Market value | — | $3.6B |
| Analysts’ mean target | — | $71.75 |
Questions
Which is bigger, Cue Biopharma or Xenon Pharmaceuticals?
Cue Biopharma is the larger company: $7.9M of revenue in its latest quarter (Q2 2026) against $7.5M for Xenon Pharmaceuticals (Q1 2025).
More: Cue Biopharma earnings · how Cue Biopharma makes money · Xenon Pharmaceuticals earnings · how Xenon Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed May 12, 2025). Fiscal quarters can end on different dates. Not investment advice.